HCW Biologics Inc (HCWB)vsInsmed Inc (INSM)
HCWB
HCW Biologics Inc
$0.39
-8.26%
HEALTHCARE · Cap: $5.36M
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 72714% more annual revenue ($606.42M vs $832,840). HCWB leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
HCWB
Avoid18
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
No standout strengths identified
No standout strengths identified
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
ROE of -277.3% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : HCWB
HCWB has a balanced fundamental profile.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : HCWB
The primary concerns for HCWB are EPS Growth, Market Cap, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
HCWB profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
INSM carries more volatility with a beta of 1.17 — expect wider price swings.
INSM is growing revenue faster at 1.5% — sustainability is the question.
HCWB generates stronger free cash flow (-3M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 18/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
HCW Biologics Inc
HEALTHCARE · BIOTECHNOLOGY · USA
HCW Biologics Inc is an innovative biotechnology firm at the forefront of developing novel immunotherapies and vaccine technologies targeting critical health challenges, including cancer and infectious diseases. Utilizing proprietary platforms that unlock the potential of the immune system, the company aims to deliver transformative biopharmaceutical solutions. With a robust pipeline of clinical candidates and strategic collaborations, HCW Biologics is well-positioned to drive advancements in patient care while addressing significant unmet medical needs, making it an attractive investment prospect for institutional investors in the growing biotechnology landscape.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?